Skip to main content
An official website of the United States government

dacomitinib

View Patient Information
A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human Her-1, Her-2, and Her-4, resulting in the proliferation inhibition and apoptosis of tumor cells that overexpress these receptors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:EGFR inhibitor PF-00299804
US brand name:Vizimpro
Code name:PF-00299804
PF-00299804-03
PF-299804
Chemical structure:(2E)-N-(4-((3-chloro-4-fluorophenyl)Amino)-7-methoxyquinazolin-6-yl)-4-piperidin-1-ylbut-2-enamide
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search